{
  "docId": "019de077-2e43-774b-aad6-58a03a29d59d",
  "docSlug": "207557819f8810b573d3e2a3179a9bac",
  "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 55 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 55,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "problem_statement",
  "function": "diagnose_problem",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "Includes references to clinical trials (CheckMate 274, AMBASSADOR, NIAGARA) and drug (Imfinzi).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-2e43-774b-aad6-58a03a29d59d/22",
  "deckHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d",
  "deckJsonHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d.json",
  "deckAnchorHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.04,
        "y": 0.78
      },
      "kind": "callout",
      "text": "NIAGARA is the first global Phase III study to evaluate a perioperative immune checkpoint inhibitor, Imfinzi, combined with neoadjuvant chemotherapy in cisplatin-eligible patients with MIBC",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "93c58235-e78b-4b44-a900-f65c261ac0c6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.92,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "list",
      "text": "Neoadjuvant cisplatin-based chemotherapy with radical cystectomy improves overall survival vs radical cystectomy alone and has been the recommended treatment for MIBC for the past 40 years, however, ~50% of patients experience recurrence within 3 years.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "30942571-6a58-452b-8a99-a7c4ab2a5b93",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.04,
        "y": 0.56
      },
      "kind": "list",
      "text": "Perioperative immune checkpoint inhibitors could improve long-term clinical outcomes by priming anti-tumour immunity before surgery and eradicating micrometastatic disease after surgery.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "537ca447-6008-4d63-9f7b-f3af660b62ad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.92,
        "x": 0.04,
        "y": 0.67
      },
      "kind": "list",
      "text": "Perioperative Imfinzi was shown to be safe and efficacious in a Phase II study of MIBC.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b23abaf2-86eb-4aa2-b732-e6075efe32b3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.92,
        "x": 0.04,
        "y": 0.41
      },
      "kind": "list",
      "text": "In the setting of MIBC, immune checkpoint inhibitors as adjuvant monotherapy have demonstrated improved disease-free survival in Phase III trials in patients at high risk of recurrence after surgery (CheckMate 274, AMBASSADOR).",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea2b1e44-f621-4869-a5ae-936cc524ea09",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.04,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "1. Yin M, et al. Oncologist 2016;21:708-715. 2. Witjes, et al. EAU Guidelines... 11. Cathomas R, et al. J Clin Oncol. 2023;41:5131-1539.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2f02d944-fe69-4027-b15f-5c0392d0d8cb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "High unmet need remains in muscle-invasive bladder cancer (MIBC)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e11d508b-68f6-45ba-860c-9e7d83dffd81",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "a656ae23-5b33-4ebe-a85a-8519a07c203b",
      "evidence": "list/bullet: Neoadjuvant cisplatin-based chemotherapy with radical cystectomy improves overall survival vs radical cystectomy alone and has been the recommended treatment for MIBC for the past 40 years, however, ~50% of",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 22,
      "from": 22,
      "beatId": "bd29e157-0501-4e1f-b25f-f2dd8dff4f68",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem (Identify pain)",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "The document highlights the high unmet need in muscle-invasive bladder cancer.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 35,
      "from": 22,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "e1d82b9f-ab34-4351-be54-5e9df327f1c4",
      "evidence": "The document highlights the high unmet need and presents NIAGARA as a solution.",
      "position": 0,
      "objective": "What is the cost of not addressing the unmet need in muscle-invasive bladder cancer?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}